APAC Influenza Antivirals Market Industry Trends and Forecast to 2034: Segmented by (Drug, Buyer, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
APAC · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$298.7 MnPlaceholder estimate
Estimate 2025$313.7 Mn24.2% of the global market
Projected 2034$486.6 Mn 55.1%Adds $172.9 Mn over 9 forecast years
CAGR 2025–20345.0%Faster than 5% of 180 Pharmaceuticals markets here
Key players5
APAC is 24.17% of the global market.
Among regions, the largest is North America at $633.6 Mn.
Roche, Shionogi, GSK PLC, BioCryst Pharmaceuticals, Cipla Inc. (see all)
Active clinical trials
56 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The APAC Influenza Antivirals Market Analysis Executive Summary
Influenza antivirals treat flu and shorten illness if started early, and are stockpiled for pandemics.
Key segments of the influenza Antivirals market include drug (Oseltamivir, Baloxavir and Zanamivir) and buyer (Retail, Hospitals and Government Stockpiles).
Asia Pacific Influenza Antivirals market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
APAC Influenza Antivirals Market Dynamics
Market Growth Drivers
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the influenza Antivirals market.
Opportunity
New vaccines, rapid tests and public-private funding for neglected diseases give the influenza Antivirals market room to grow, especially in Asia, Africa and Latin America.
Market Restraints
Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the influenza Antivirals market.
Competitive Landscape for Influenza Antivirals Market in APAC
The influenza Antivirals market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Influenza Antivirals Market in APAC
Influenza Antivirals in APAC: rules, payment and research
In some of the countries we cover here, medicines are approved by TGA (Australia)[1], NMPA (China)[2], Drug Office (Hong Kong)[3], CDSCO (India)[4], PMDA (Japan)[5], NPRA (Malaysia)[6], Medsafe (New Zealand)[7], FDA Philippines (Philippines)[8], HSA (Singapore)[9] and Thai FDA (Thailand)[10]. How care is paid for in some of these countries: Medicare and the PBS (Australia)[11], basic medical insurance (China)[12], the Hospital Authority (Hong Kong)[13], Ayushman Bharat PM-JAY (India)[14], public health insurance (Japan)[15], subsidised public care (Malaysia)[16], Pharmac (New Zealand)[17], PhilHealth (Philippines)[18], MediShield Life (Singapore)[19] and the Universal Coverage Scheme (Thailand)[20]. ClinicalTrials.gov lists 56 studies on Influenza Antivirals that are recruiting, active or about to start in APAC.[21]
[21]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for influenza Antivirals. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Drug
4.2 By Buyer
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Roche
7.2 Shionogi
7.3 GSK
7.4 BioCryst Pharmaceuticals
7.5 Cipla
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The influenza Antivirals market can be segmented based on various criteria, including drug, buyer and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Source: WHO Prequalification, Vaccines, tests and medicines on the WHO prequalified lists that match this market. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Influenza Antivirals right now, from free public sources.
Clinical trials
56 active trials in China, India, Japan, Australia, Hong Kong, Philippines, Singapore, Thailand, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan
Recruiting, about to start, or running now. Counted across the 16 countries we report on in APAC.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
How big is the Influenza Antivirals market in Asia Pacific?
Placeholder estimate: about $313.7 Mn in 2025, rising to about $486.6 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Influenza Antivirals market in Asia Pacific growing?
Placeholder estimate: about 5.0% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Influenza Antivirals market report cover?
The report splits the market by drug (Oseltamivir, Baloxavir, Zanamivir, Peramivir), buyer (Retail, Hospitals, Government Stockpiles) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Influenza Antivirals market?
Key players include Roche, Shionogi, GSK PLC, BioCryst Pharmaceuticals and Cipla Inc..
What is driving the Influenza Antivirals market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the influenza Antivirals market.
How many clinical trials on Influenza Antivirals are running in Asia Pacific?
56 studies are recruiting, active or about to start in Asia Pacific, counted across the 16 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
How much research is published on Influenza Antivirals?
PubMed lists 47 papers on Influenza Antivirals added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.